✦ LIBER ✦

Myelofibrosis, JAK2 inhibitors and erythropoiesis

✍ Scribed by Vainchenker, W; Favale, F

Book ID: 120399890
Publisher: Nature Publishing Group
Year: 2013
Tongue: English
Weight: 339 KB
Volume: 27
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2013.72

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapy of myelofibrosis (excluding JAK2

Therapy of myelofibrosis (excluding JAK2 inhibitors)

✍ Alessandro Rambaldi 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 189 KB

Ruxolitinib, an oral JAK1 and JAK2 inhib

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

✍ Vaddi, Kris; Sarlis, Nicholas J; Gupta, Vikas 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 545 KB

Therapy with JAK 1/2 inhibitors for myel

Therapy with JAK 1/2 inhibitors for myelofibrosis

✍ Franz Romeder MD, Richard Greil… 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 277 KB

How many JAK inhibitors in myelofibrosis

How many JAK inhibitors in myelofibrosis?

✍ Ferreira, Bruna Velosa; Harrison, Claire 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 247 KB

Hypothesis: How do JAK2-inhibitors work

Hypothesis: How do JAK2-inhibitors work in myelofibrosis

✍ Ruben Mesa; Robert Peter Gale 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 205 KB

JAK2-inhibitors rapidly reduce spleen enlargement and clinical symptoms in persons with myelofibrosis but have little, if any, effect on the WBC, anemia, decreased platelets or bone marrow fibrosis. Also, JAK2-inhibitors are active in persons with and without the JAK2-mutation. Based on these and ot

Safety and Efficacy of INCB018424, a JAK

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

✍ Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cor 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 542 KB